Pathios Therapeutics ("Pathios"), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery ("Sygnature"), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes.
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
When Art Ashkin, Steve Chu, and their colleagues at Bell Labs in Holmdel, NJ, first invented optical tweezers, they spent their days pushing around tiny, glass spheres.
Efforts are under way to develop a vaccine against one of the world's deadliest illnesses, cervical cancer. Along with a number of university research laboratories, at least a half-dozen biotechnology and pharmaceutical companies are beginning clinical trials or are in preclinical development of such drugs. Efficacy in humans remains to be firmly established, but if the vaccines progress to later-phase trials, challenging jobs for immunologists, microbiologists, and biochemists will multiply. "
With human research trials resulting in dozens of successful deliveries in the US and abroad, doctors move toward offering the surgery clinically, while working to learn all they can about uterine and transplant biology from the still-rare procedure.